Tscan Therapeutics earnings were -$117.7M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest TCRX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$30.4M, up 5.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TCRX reported annual earnings of -$129.8M, with 1.8% growth. The next TCRX earnings date is Nov 11, 2026.
What were Tscan Therapeutics's earnings last quarter?
On TCRX's earnings call on Aug 11, 2026, Tscan Therapeutics (NASDAQ: TCRX) reported Q2 2026 earnings per share (EPS) of -$0.23, up 17.86% year over year. Total TCRX earnings for the quarter were -$30.36 million. In the same quarter last year, Tscan Therapeutics's earnings per share (EPS) was -$0.28.
The next TCRX earnings date is Nov 11, 2026. Add TCRX to your watchlist to be reminded of Tscan Therapeutics's next earnings date.
Is Tscan Therapeutics profitable or losing money?
As of the last Tscan Therapeutics earnings report, Tscan Therapeutics is currently losing money. Tscan Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$117.71 million, a 13.94% decrease year over year.
What was TCRX's earnings growth in the past year?
As of Tscan Therapeutics's earnings date in Aug 11, 2026, Tscan Therapeutics's earnings has grown year over year. TCRX earnings in the past year totalled -$117.71 million.
What are Tscan Therapeutics's earnings expectations?
The current EPS estimate for Tscan Therapeutics's earnings report in Nov 11, 2026 is -$0.26.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.